Loading clinical trials...
Loading clinical trials...
A Phase 2 study to evaluate the safety and efficacy of two different once daily doses VX-135 in combination with ribavirin in treatment-naïve subjects with chronic hepatitis C
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Vertex Pharmaceuticals Incorporated
NCT03993925 · Chronic Hepatitis C, Intravenous Drug Usage
NCT00199719 · Chronic Hepatitis C
NCT06922643 · Chronic Hepatitis C
NCT01340573 · Chronic Hepatitis C
NCT01120795 · Chronic Hepatitis C
California
La Jolla, California
Florida
Orlando, Florida
Georgia
Marietta, Georgia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions